Abstract
Colorectal cancer is the third leading cause of cancer-related death. The survival rate is significantly lower for patients with metastatic colorectal cancer (mCRC). Moreover, most patients with mcRC develop resistance to chemotherapy. Therefore, effective new treatment is needed. Panitumumab is the first fully humanized monoclonal therapeutic antibody that selectively binds epidermal growth factor receptor (EGFR), interrupts the intracellular signaling EGFR and results in antitumor effect. Panitumumab has shown safety and antitumor activity for the treatment of patients with chemorefractory mCRC in clinical trials, and may be an effective option for radioimmunoimaging and radioimmunotherapy. Key words: Panitumumab; Metastatic colorectal cancer; Epidermal growth factor receptor; Molecular targeted treatment
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
